Trial record 1 of 1 for:    PDX-017
Previous Study | Return to List | Next Study

Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01420679
Recruitment Status : Terminated
First Posted : August 22, 2011
Last Update Posted : May 2, 2018
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc

Brief Summary:
The purpose of this study is to see if pralatrexate extends response and survival following CHOP-based chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) and if pralatrexate improves response in patients with partial response following CHOP-based chemotherapy. Patients will either receive pralatrexate or be under observation. All patients will receive vitamins B12 and folic acid and attend regular clinic visits to evaluate their disease and health.

Condition or disease Intervention/treatment Phase
Peripheral T-cell Lymphoma Drug: Pralatrexate Injection Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy
Study Start Date : August 2011
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Pralatrexate
Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.
Drug: Pralatrexate Injection

Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).

Initial dose: 30 mg/m2

Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met.

Other Names:
  • PDX
  • Pralatrexate
  • (RS)-10-propargyl-10-deazaaminopterin

No Intervention: Observation
Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.

Primary Outcome Measures :
  1. Progression-free Survival (PFS) [ Time Frame: Assessed at 8 weeks (+/-1 wk) then every 12 weeks (+/-1 wk) through 3 years, then every 24 weeks (+/-4 wks) until progression of disease (PD) or up to 7 years post-randomization ]
  2. Overall Survival (OS) [ Time Frame: Collected approximately every 6 months after documented PD through 7 years post-randomization ]

Secondary Outcome Measures :
  1. Objective Response to Pralatrexate versus Observation [ Time Frame: Assessed at 8 weeks (+/-1 wk) then every 12 weeks (+/-1 wk) through 3 years, then every 24 weeks (+/-4 wks) until progression of disease (PD) or up to 7 years post-randomization ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has one of the following peripheral T-cell lymphoma (PTCL) subtypes confirmed by an independent central pathology reviewer, using the Revised European American Lymphoma World Health Organization disease classification:

    • T/natural killer (NK)-cell leukemia/lymphoma
    • Adult T-cell lymphoma (TCL)/leukemia (human T-cell leukemia virus 1+)
    • Angioimmunoblastic TCL
    • Anaplastic large cell lymphoma (ALCL), primary systemic type, excluding anaplastic lymphoma kinase positive (ALK+) with International Prognostic Index (IPI) score less than 2 at initial diagnosis and complete response (CR) after CHOP-based therapy
    • PTCL-unspecified
    • Enteropathy-type intestinal lymphoma
    • Hepatosplenic TCL
    • Subcutaneous panniculitis TCL
    • Transformed mycosis fungoides (tMF)
    • Extranodal T/NK-cell lymphoma nasal or nasal type
    • Primary cutaneous gamma-delta TCL
    • Primary cutaneous CD8+ aggressive epidermic cytotoxic TCL
  • Documented completion of at least 6 cycles of CHOP-based therapy:

    • CHOP 21
    • CHOP 14
    • CHOP + etoposide
    • Other CHOP variants: substitution allowed for 1 component with a drug of the same mechanism of action. Additional components, except alemtuzumab, are allowed. Rituximab may be added if not given within 3 cycles of randomization.
  • Patient has achieved CR or partial response (PR) per per investigator's assessment following completion of CHOP-based therapy and has had radiological assessment within 21 days prior to randomization.
  • Eastern Cooperative Oncology Group performance status less than or equal to 2.
  • Adequate blood, liver, and kidney function as defined by laboratory tests.
  • Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate.
  • Men who are sexually active, including those with a pregnant partner, must agree to practice a medically acceptable barrier method contraceptive regimen (eg, condoms) while receiving pralatrexate and for 90 days after the last administration of pralatrexate.
  • Has given written informed consent.

Exclusion Criteria:

  • Patient has:

    • Precursor T/NK neoplasms
    • ALCL (ALK+) with IPI score less than 2 at initial diagnosis and CR after CHOP-based therapy
    • T cell prolymphocytic leukemia
    • T cell large granular lymphocytic leukemia
    • Mycosis fungoides, except tMF
    • Sézary syndrome
    • Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis
  • If there is a history of prior malignancies other than those below, must be disease free for at least 5 years. Patients with malignancies listed below less than 5 years before study entry may be enrolled if they have received treatment resulting in complete resolution of the cancer and have no clinical, radiologic, or laboratory evidence of active/recurrent disease.

    • non-melanoma skin cancer
    • carcinoma in situ of the cervix
    • localized prostate cancer
    • localized thyroid cancer
  • Receipt of prior chemotherapy (CT) or radiation therapy (RT) for PTCL, other than a single allowed CHOP regimen, except:

    • Patients with nasal NK lymphoma who received local RT less than 4 weeks prior to randomization.
    • Patients with tMF who received 1 systemic single-agent CT (except methotrexate) prior to transformation.
  • Prior exposure to pralatrexate.
  • Receipt of systemic corticosteroids within 3 weeks of study treatment, unless patient has been taking a continuous dose of 10 mg/day or less of oral prednisone or equivalent for at least 4 weeks or as part of a CHOP prednisone taper.
  • Planned use of any treatment for PTCL during the course of the study.
  • Patient has:

    • Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than 100 mm3 or detectable viral load within past 3 months and receiving anti-retroviral therapy.
    • Hepatitis B (HBV)-positive serology and is receiving interferon therapy or has liver function test results outside the parameters of study inclusion criteria. Other antiviral therapies are permitted if at a stable dose for at least 4 weeks.
    • Hepatitis C (HCV) virus with detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy.
    • Symptomatic central nervous system metastases or lesions requiring treatment.
    • Uncontrolled hypertension or congestive heart failure Class III/IV per the New York Heart Association's Heart Failure Guidelines
    • Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness impairing the ability of the patient to receive protocol treatment.
  • Major surgery within 2 weeks prior to study entry, except for line placement or biopsy procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01420679

  Hide Study Locations
United States, Michigan
Detroit Clinical Research Center, PC
Novi, Michigan, United States, 48377
United States, New York
New York Presbyterian Hospital
New York, New York, United States, 10021
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Flinders Medical Center
Bedford Park, South Australia, Australia, 5042
Australia, Tasmania
Royal Hobart Hospital
Hobart, Tasmania, Australia, 7001
Australia, Victoria
Monash Medical Centre
Clayton, Victoria, Australia, 3168
Saint Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia, 3109
Frankston Hospital
Frankston, Victoria, Australia, 3199
Cabrini Health
Malvern, Victoria, Australia, 3144
Australia, Western Australia
Royal Perth Hospital
Perth, Western Australia, Australia, 6000
AZ Sint-Jan
Brugge, Belgium, 8000
Universitair Ziekenhuis Gent
Gent, Belgium, 9000
Canada, Ontario
Sunnybrook Health Science Centre
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Hôpital du Sacré-Coeur de Montréal
Montreal, Quebec, Canada, H4J 1C5
Hôpital Morvan
Brest, France, 29609
CHU Haut-Leveque
Pessac, France, 33604
St James Hospital
Dublin 8, Ireland
Shaare Zedek Medical Center
Jerusalem, Israel, 91031
Hadassah Ein-Kerem Medical Centre
Jerusalem, Israel, 91120
Rabin Medical Center
Petach Tikva, Israel, 49100
Chaim Sheba Medical Center
Tel Hashomer, Israel, 52621
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Forli, Italy, 47014
Az. Ospedaliera Universitaria S. Orsola Malpighi
Bologna, Italy, 40138
Spedali Civili di Brescia
Brescia, Italy, 25123
Ospedale S. Maria delle Croci
Ravenna, Italy, 48121
Università Cattolica del Sacro Cuore
Roma, Italy, 00168
Az. Ospedaliera Università Senese
Siena, Italy, 53100
New Zealand
Middlemore Hospital
Otahuhu, Auckland, New Zealand, 1640
Auckland City Hospital / Auckland University
Auckland, New Zealand, 1010
Christchurch Hospital
Christchurch, New Zealand, 8011
North Shore Hospital
Milford, New Zealand
Klinika Nowotworów Ukladu Chlonnego Centrum Onkologii Instytut Marii Sklodowskiej-Curie
Warszawa, Mazowieckie, Poland, 02-781
Dept of Hematology and Transplantology
Gdansk, Poland, 80-952
Małopolskie Centrum Medyczne
Kraków, Poland, 30-510
Puerto Rico
Auxilio Mutuo Cancer Center
San Juan, Puerto Rico, 00918
Clinica Universidad de Navarra
Pamplona, Navarra, Spain, 31008
Complejo Hospitalario de Navarra, Servicio de Hematologia
Pamplona, Navarra, Spain, 31008
Complejo Hospitalario Universitario A Coruña- Hospital A Coruña
A Coruña, Spain, 15006
Hospital General Vall d'Hebron
Barcelona, Spain, 08035
Hospital Clínic i Provincial de Barcelona
Barcelona, Spain, 08036
Hospital Universitario Ramón y Cajal
Madrid, Spain, 28034
Hospital de Madrid Norte-Sanchinarro
Madrid, Spain, 28050
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain, 28222
United Kingdom
Royal Cornwall Hospital
Truro, Cornwall, United Kingdom, TR1 3LJ
Poole Hospital NHS Foundation Trust, Poole General Hospital
Poole, Dorset, United Kingdom, BH15 2JB
Derriford Hospital
Devon, England, United Kingdom, PL68DH
Sandwell & West Birmingham Hospitals NHS Trust
West Bromwich, England, United Kingdom, B71 4HJ
Antrim Area Hospital
County Antrim, Northern Ireland, United Kingdom, BT41 2RL
NHS Greater Glasgow and Clyde Western Infirmary
Glasgow, Scotland, United Kingdom, G11 6NT
Belfast City Hospital
Belfast, United Kingdom, BT9 7AB
Velindre Hospital
Cardiff, United Kingdom, CF14 2TL
Royal Liverpool University Hospital
Liverpool, United Kingdom, L7 8XP
Mount Vernon Cancer Centre
Middlesex, United Kingdom, HA6 2RN
UHCW (University Hospital Coventry and Warwickshire)
Warwick, United Kingdom, CA34 5BW
Sponsors and Collaborators
Spectrum Pharmaceuticals, Inc
Study Director: Pankaj Sharma, MD Spectrum Pharmaceuticals, Inc

Responsible Party: Spectrum Pharmaceuticals, Inc Identifier: NCT01420679     History of Changes
Other Study ID Numbers: PDX-017
2010-022230-81 ( EudraCT Number )
First Posted: August 22, 2011    Key Record Dates
Last Update Posted: May 2, 2018
Last Verified: April 2018

Keywords provided by Spectrum Pharmaceuticals, Inc:
Lymphoproliferative Disorders
Non-Hodgkin's Lymphoma
T-cell Lymphoma

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents